- $2.83bn
- $2.89bn
- $354.34m
- 81
- 24
- 62
- 56
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 38.47 | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.7 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | 41.98 | ||
Price to Sales | 7.99 | ||
EV to EBITDA | 188.72 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -2.85% | ||
Return on Equity | -5.21% | ||
Operating Margin | -11.51% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 208.51 | 243.53 | 286.1 | 335.64 | 354.34 | 388.54 | 430.31 | 16.7% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +20.51 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.
Directors
- Sherilyn McCoy NEC (62)
- William Feehery CEO (51)
- M. Andrew Schemick CFO (47)
- Robert Aspbury CEX (49)
- Justin Edge CEX (52)
- Leif Pedersen CEX (56)
- Patrick Smith CEX
- Judith Dickinson CHO (47)
- Richard Traynor SVP (49)
- Jieun Choe CMO (46)
- Cynthia Collins DRC (63)
- Nancy Killefer DRC
- James Cashman IND (67)
- Carol Gallagher IND (56)
- Eric Liu IND (44)
- Stephen McLean IND (63)
- Mason Slaine IND (68)
- Matthew Walsh IND (54)
- Ethan Waxman IND (32)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 27th, 2017
- Public Since
- December 11th, 2020
- No. of Shareholders
- 34
- No. of Employees
- 1,338
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 160,191,094
- Address
- 100 Overlook Center, Suite 101, PRINCETON, 08540
- Web
- https://www.certara.com/
- Phone
- +1 6097167900
- Auditors
- RSM US LLP
Upcoming Events for CERT
Q1 2024 Certara Inc Earnings Call
Certara Inc at Bank of America Health Care Conference
Certara Inc Annual Shareholders Meeting
Q2 2024 Certara Inc Earnings Release
Similar to CERT
2U
NASDAQ Global Select Market
ACV Auctions
NASDAQ Global Select Market
Adeia
NASDAQ Global Select Market
Adobe
NASDAQ Global Select Market
Agilysys
NASDAQ Global Select Market
FAQ
As of Today at 19:05 UTC, shares in Certara are trading at $17.67. This share price information is delayed by 15 minutes.
Shares in Certara last closed at $17.67 and the price had moved by -25.69% over the past 365 days. In terms of relative price strength the Certara share price has underperformed the S&P500 Index by -39.99% over the past year.
The overall consensus recommendation for Certara is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Certara does not currently pay a dividend.
Certara does not currently pay a dividend.
Certara does not currently pay a dividend.
To buy shares in Certara you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $17.67, shares in Certara had a market capitalisation of $2.83bn.
Here are the trading details for Certara:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CERT
Based on an overall assessment of its quality, value and momentum Certara is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Certara is $19.72. That is 11.6% above the last closing price of $17.67.
Analysts covering Certara currently have a consensus Earnings Per Share (EPS) forecast of $0.43 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Certara. Over the past six months, its share price has outperformed the S&P500 Index by +9.78%.
As of the last closing price of $17.67, shares in Certara were trading +8.12% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Certara PE ratio based on its reported earnings over the past 12 months is 38.47. The shares last closed at $17.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Certara's management team is headed by:
- Sherilyn McCoy - NEC
- William Feehery - CEO
- M. Andrew Schemick - CFO
- Robert Aspbury - CEX
- Justin Edge - CEX
- Leif Pedersen - CEX
- Patrick Smith - CEX
- Judith Dickinson - CHO
- Richard Traynor - SVP
- Jieun Choe - CMO
- Cynthia Collins - DRC
- Nancy Killefer - DRC
- James Cashman - IND
- Carol Gallagher - IND
- Eric Liu - IND
- Stephen McLean - IND
- Mason Slaine - IND
- Matthew Walsh - IND
- Ethan Waxman - IND